Genprex goes public
Austin, Texas-based Genprex Inc, a developer of immunogene therapy for non-small cell lung cancer, has raised $6.4 million for its IPO after pricing its 1.28 million shares at $5 per share. The stock began trading March 29, 2018 on the NASDAQ under the ticker symbol "GNPX." Network 1 Financial Securities Inc was the sole bookrunner. Genprex's pre-IPO backers include Inception Capital Management.
29 March 2018•2 mins read
